دعائى لكل مريض

يارب إن قدرتك تفوق قدرة الأطباء، فأنزل علىٰ كل مريض شفاءً من السماء اللهم اشف من هم علىٰ فراش المرض يأنون وبأجسادهم يتألمون أ.م.د.وئام أحمد العاملي

### MOLECULAR SUBTYPES OF BREAST CANCER BY Assist. Prof. Dr. Wiaam Ahmed Al- Amili





Cancer


Cancer is the abnormal, uncontrollable, continuous replication of cells which will inevitably lead to the formation of a tumor.




# Breast cancer

Forms in the tissues of the breast Spreads mainly through the Lymphatic system

#### THE NORMAL BREAST



- 1. Chest wall.
- 2. Pectoral muscles.
- 3. Lobules (glands that make milk).
- 4. Nipple surface.
- 5. Areola.
- 6. Lactiferous duct tube that carries milk to the nipple
- 7. Fatty tissue.
- 8. Skin.



### **BREAST TUMORS**

#### Malignant

#### Cancerous

#### Benign

#### Not - Cancerous

### **BENIGN TUMORS**

Not cancerous.

Benign breast tumors are abnormal growths, but they do not spread outside of the breast and they are not life threatening.


### **BENIGN TUMORS**

 Most lumps are caused by the combination of cysts and fibrosis

□ Cysts are fluid-filled sacs.

■ Fibrosis is the formation of scar - like tissue.

These changes can cause breast swelling and pain.



 Cancer
 Breast cancer is a malignant (cancerous) tumor that starts in the cells of the breast. It is found mostly in women, but men can get breast cancer, too.

Breast


# Breast Cancer


Invasive

Non - Invasive

- Cancerous
- Malignant
- Spreads to other organs (metastasis)

- Pre Cancerous
- Still in its original position
- Eventually develops into invasive breast cancer.





## Breast Cancer

The inner lining of milk ducts.

The lobules – Milk producing glands.

Ductal Carcinoma

Lobular Carcinoma

#### **TYPES OF BREAST CANCER**

Ductal Carcinoma Inflammatory Breast Cancer (IBC)

Invasive Ductal Carcinoma

Ductal Carcinoma in situ (DCIS) Invasive Lobular Carcinoma

Lobular

Carcinoma

Lobular Carcinoma in situ (LCIS)

#### FACTORS THAT CONTRIBUTES TO BREAST CANCER

Gender

Age

Genetic risk factors

Family history

Personal history of breast cancer

#### FACTORS THAT CONTRIBUTES TO BREAST CANCER

Race/ethnic background

Dense breasts tissue

Certain benign (not cancer) breast problems

Menstrual periods

Breast radiation early in life

Despite surgery, cytotoxic chemotherapy, hormonal therapy, and/or regional radiotherapy, ~ 30% of patients will eventually experience disease recurrence and resistance to treatment are poorly understood. **Predict Chances of Relapse** 

### **Tumor Markers**

➤Tumor markers are substances that can be found in abnormal amounts in the blood, urine and tissues of some patients with cancer.

Markers are needed to predict cancer progression and the risk of late recurrence .

- A small number of single biomarkers, including
- Estrogen receptor (ER)
- Progesterone receptor (PR)
- Human Epidermal growth factor Receptor-2(HER2)
- proliferation marker Ki-67

-These markers have been used for to predict the prognosis of breast cancer and guide effectiveness of therapy

### Ki 67

 $\gg$ t's a protein in cells that is involved in cell replication, so if many cells are expressing it, the tumor is growing quickly; if very few cells express it, then it is growing slowly.

Ki-67 is an excellent marker to determine the growth fraction of a given cell population

A special stain that gives a sense of how aggressive a tumor is. The pathologist takes the biopsy or surgical specimen, prepares it, puts it on to a glass slide, stains it for this protein, and look at it under the microscope. The pathologist needs to count about a thousand cells and determine the

percentage of cells that are Ki67 positive.

- ➤Therefore, the number that comes back should be a percentage from 0 100%.
- An general, if the Ki67 is :
- -between 0-2%, then we call it grade 1 or low grade.
- -If it is between 2-20%, we call it grade 2 or intermediate grade.
- -If it is > 20%, then it is grade 3 or high grade.
- -The good, the bad, and the ugly.

#### **Cytokeratins** (CK)

≻Cytokeratins are keratin proteins found in the intracytoplasmic cytoskeleton of epithelial tissue.

➤They are an important component of intermediate filaments, which help cells resist mechanical stress.

Thus they are used clinically to identify the cell of origin of various human tumors

### **Cytokeratin (CK)**

- ≯s a Tumor marker .
- The different types of cytokeratins are numbered based on where they are found in the body.
  CK5 positivity helps define a basal-like subtype of triple negative breast carcinoma (TNBC) with poorer prognosis

Amplification or over-expression of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of breast cancer. An recent years the protein has become an

important biomarker and target of therapy
for approximately 30% of breast
cancer patients

### HER2/neu

> *HER2/neu:* growth-promoting protein >HER2 (from human epidermal growth factor receptor 2) or HER2/neu also known Receptor tyrosine-protein kinase ERBB-2 (erythroblastic oncogene B). HER2 is a member of the human Epidermal Growth Factor Receptor (HER / EGFR / ERBB )

family .

### **Breast Cancer**

➢Breast cancer is a very complex, heterogeneous and phenotypically diverse disease.

➢It's different subtypes have distinct behavior and response to therapy Breast tumors are classified by their hormone-receptor status and by the presence, or absence, of certain proteins.

The type of tumor determines how the disease will be treated.

- Breast Cancers were divided into:
- hormone receptor positive
- hormone negative tumours.

# Breast carcinomas were classified into four main molecular subtypes :

- 1- Luminal A: ER/PR(+) / HER2(-)
- 2- Luminal B/Triple Positive: ER/PR(+) / HER2(+)
- 3- Non-Luminal/Triple Negative: ER/PR(-) and HER2(-)
- 4- Non-Luminal HER-2 enriched: ER/PR(-) / HER2(+)

Other phenotypes included: ER(+)/ PR(-) / HER2(+) ER(-)/ PR(+) / HER2 (+) ER (+)/PR (-) / HER2 (-) ER (-)/PR (+) / HER2 (-). Roughly **65-75%** of breast cancer patients have **hormone-receptor-positive breast cancer**. These HR+ tumors may be stimulated by either

estrogen or progesterone.

Treatment for HR+ breast cancer usually includes medications such as **tamoxifen or aromatase inhibitors**. These hormonal therapies block the activity of estrogen.





About 20% of breast cancer tumors are HER2-positive. Half of these tumors are also hormone-receptor-positive. HER2 stands for human epidermal growth factor 2, a gene that expresses the HER2-receptor protein. This receptor is important in the normal growth of breast cells. But, in excess, the HER2 receptor can cause cancer cells to grow.



Treatment for HER2-positive tumors typically includes

- Drugs that target the HER2 receptor, such as Herceptin (trastuzumab)
- Chemotherapy

This combination helps block the HER2 signaling pathway, stopping cancer cell growth.



# Triple-negative breast cancer means the tumors tested negative for

- Estrogen receptors,
- Progesterone receptors, and
- HER2 receptors

E

Triple-negative breast cancer affects roughly **15% of breast cancer patients**, and tends to be more aggressive than the other two subtypes. Younger women, women of African American descent, and those with a *BRCA1* genetic mutation tend to be more likely to develop triple-negative breast cancer.



Since triple-negative tumors lack hormone and HER2 receptors, chemotherapy provides the backbone for treatment, particularly platinum chemotherapy.

Many new targets for this tumor subtype are being studied in clinical trials.



## Luminal A

(i)ER and/or PR +, HER2/neu -ve (ii)Most common (iii)Luminal A : possess a higher expression of the ER and estrogen-associated genes ESR1, GATA3 and FOXA1 (iv)Ki-67 proliferation index which helps control how fast cancer cells grow- tend to grow slowly low... low-grade. (v)Associated with a better prognosis

are likely to benefit from hormone therapy and may also benefit from chemotherapy.

### Luminal B (Triple Positive)

(i)ER and/or PR+ HER2+

(ii)Variable HER2/neu expression

(iii)Increased frequency of TP53 mutations

(iv)Ki-67 proliferation index- high... generally

grow slightly faster than luminal A cancers

(v)Associated with worse prognosis

compared to Luminal A

➢ikely to benefit from chemotherapy
➢may benefit from hormone therapy
➢may benefit from treatment targeted to HER2.

#### **Basal – Like Subtype (Triple negative)**

- •ER and PR and HER2/neu —
- Hormone receptor (ER and PR) and HER2/neu
- receptor negative .
- Aggressive with a poorer disease-free and overall
- survival than the other breast cancer subtypes

This type of cancer is more common in women with *BRCA1* gene mutations. Researchers aren't sure why, but this type of cancer also is more common among younger and Black women.

They are usually treated with some combination of surgery, radiation therapy and chemotherapy. >Triple negative tumors aren't treated with hormone therapy because they are ER-negative A standard **triple-negative chemo** regimen is 12 weeks of **taxol**, followed by four doses of **adriamycin** and **cytoxan**. new study, doctors gave patients In the an additional chemo drug called carboplatin

#### **HER2/neu Over Expression**

- ER- PR- HER2+ -non luminal / HER2+ -low expression of ER and PR -HER2-enriched cancers tend to grow faster than luminal cancers and can have a worse prognosis ... Poor clinical outcome. -Associated with a high histological grade,

They are often successfully treated with targeted therapies aimed at the HER2 protein, such as 1- Enhertu (chemical name: fam-trastuzumabderuxtecan-nxki) 2- Herceptin (chemical name: trastuzumab), 3- Perjeta (chemical name: pertuzumab), 4- Tykerb (chemical name: lapatinib), 5- Nerlynx (chemical name: neratinib), 6- Kadcyla (chemical name: T-DM1 or ado-trastuzumab emtansine).

Subtype	Phenotype	Type of Treatment
Luminal A	ER + PR +/- , HER2/neu - Ki 67low ( $\leq 14$ )	Endocrine therapy alone
Luminal B (HER2 positive)	ER + PR +/, HER2/neu + Ki 67high (> 14 )	Endocrine + anti-HER2 <u>+</u> Cytotoxic therapy
Luminal B (HER2 negative)	ER + PR +/- , HER2/neu - Ki 67 (>14)	Endocrine <u>+</u> Cytotoxic therapy
Basal-Like (Triple negative) (Ductal)	ER _ PR _ and HER2/neu _	Cytotoxic therapy
HER2/neu Over expression (non- luminal	ER — PR — and HER2/neu +	anti-HER2 <u>+</u> Cytotoxic therapy



Assist. Prof. Dr. Wiaam Ahmed Al-Amili











